- Madrigal Pharmaceuticals ( NASDAQ: MDGL ) said that an analysis of phase 3 data on resmetirom further reinforces the drug's efficacy at resolving nonalcoholic steatohepatitis ( NASH ) compared to placebo.
- At 52 weeks of treatment, the consensus read support analysis showed, respectively, that 24% and 28% achieved NASH resolution with resmetirom 80 mg and 100 mg with ?2-point reduction in NAFLD activity score (NAS) compared to just 8% on placebo.
- A second primary endpoint, ?1-stage improvement in fibrosis with no worsening of NAS, was achieved with, respectively, 24% and 26% of those on resmetirom 80 mg and 100 mg compared to 12% on placebo.
- The new results are being presented at a medical conference Friday.
- When it first posted data on the trial in December, Madrigal ( MDGL ) surged 268%.
For further details see:
Madrigal Pharmaceuticals releases additional late-stage data on resmetirom for NASH